Vinorelbine and Infusional 5-fluorouracil in Anthracycline and Taxane Pre-treated Metastatic Breast Cancer

Stuart, N.; McIllmurray, M B; Bishop, Jill; Johnston, Stephen; Price, C. H. G.; O’Reilly, Susan; Joffe, Johnathan; Neave, F.; Whipp, E.

doi:10.1016/j.clon.2007.10.013

Cited by 8 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Capecitabine is efficacious and widely used, as for years it was the only Food and Drug Administration‐approved option in this particular clinical setting (19). In addition, vinorelbine has demonstrated some efficacy in taxane‐ and anthracycline‐resistant MBC in small phase II trials (20,21), but is not yet approved for this indication. Although gemcitabine is often used in clinical practice to treat tumors not amenable to taxane or anthracycline therapy, little evidence supports that monotherapy is efficacious in this setting (22).…”

Section: Clinical Approaches To Taxane and Anthracycline Resistancementioning

confidence: 99%

Overcoming Taxane and Anthracycline Resistance

Zelnak

2010

The Breast Journal

View full text Add to dashboard Cite

With more and more breast cancer (BC) patients receiving taxanes and anthracyclines in the adjuvant setting, the number of patients resistant to these drugs is rising. Herein, we review cellular mechanisms (e.g., overexpression of drug efflux pumps) that are associated with clinical anthracycline and/or taxane-resistant BC. We also discuss therapeutic approaches that have received Food and Drug Administration approval in this setting or are in clinical development, including targeted agents that do not employ a cytotoxic mechanism, as well as novel chemotherapeutics such as the epothilones, a class of microtubule stabilizers less susceptible to common cellular resistance mechanisms.

show abstract

Section: Clinical Approaches To Taxane and Anthracycline Resistancementioning

confidence: 99%

Overcoming Taxane and Anthracycline Resistance

Zelnak

2010

The Breast Journal

View full text Add to dashboard Cite

show abstract

“…Literature reports response rates between 22 and 70% for the combination VNB-FU when results are expressed following the intention to treat. Wide variation in outcome among different phase II studies is a well known phenomenon which is mainly due to patients selection (Berruti et al 2000;Stuart et al 2008). No complete response was recorded.…”

Section: Discussionmentioning

confidence: 99%

“…The association of infusion FU and VNB has been already studied in various phase II studies with an overall response rate (ORR) ranging from 34 to 70% and an overall survival (OS) up to 23 months (Stuart et al 2008). Although the association of the De Gramont FU/LV schedule with VNB was reported only as retrospective analysis by Gebbia et al with a 48% response rate, acceptable toxicities and a OS of 14.6 months (Gebbia et al 2006).…”

Section: Introductionmentioning

confidence: 98%

Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study

Oliva

Bergnolo

Inguì

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Results demonstrate that the ViFL regimen has substantial activity in patients with MBC already treated with anthracyclines and taxanes. The combination may be considered a valid choice for the treatment of MBC. Better survival results were seen in patients with visceral metastases than bone involvement. The low response rate shows that the ViFL regimen is not suitable for the neoadjuvant setting.

show abstract

“…Clinically, 5-fluorouracil (5-Fu) has been commonly used as a single agent or in combination with other chemotherapies in breast cancer treatment for decades [ 15 – 17 ]. Continuous infusional 5-Fu combined with epirubicin and cisplatin (ECciF) regimen appears to be more active than conventional regimens for both advanced breast cancer and large operable breast cancer, but the contribution of 5-Fu to the anthracycline–cyclophosphamide regimens (AC or EC) has not been well defined [ 18 , 19 ].…”

Section: Discussionmentioning

confidence: 99%

A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer

Zhou

Ouyang

Xie

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

This study aimed to compare the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer. Five-hundred and one patients with clinical stage I–III invasive breast cancer were randomly assigned to receive four cycles of neoadjuvant chemotherapy with either CEFci arm (5-Fu 200 mg/m2 daily by 24-h continuous infusion and epirubicin 100 mg/m2 and cyclophosphamide 600 mg/m2 intravenous bolus on day 1), CEF arm (cyclophosphamide 600 mg/m2, epirubicin 100 mg/m2, and 5-Fu 600 mg/m2 i.v. on day 1), or EC arm (epirubicin 100 mg/m2 and cyclophosphamide 600 mg/m2 i.v. on day 1). The pathologic responses to chemotherapy were assessed according to the Miller and Payne grading system (MP). A total of 485 patients were included in the intent-to-treat population. Breast pathologic complete response (pCR) rate was 18.9 % (31/164) in CEFci arm, 15.0 % (24/160) in CEF arm, and 12.4 % (20/161) in EC arm (P = 0.266). MP grading system 4/5 response rate was significantly higher in CEFci arm than that in CEF arm and EC arm (44.5, 31.3 and 27.3 %, respectively, P = 0.003). There was no significant difference on grade III/IV neutropenia among three arms (P = 0.538), but thrombocytopenia, decreased hemoglobin, and elevated aminotransferase appeared to be observed more in CEFci arm (P = 0.040, 0.059, and 0.073, respectively). CEFci did not reach a higher pCR rate compared with CEF or EC in patients with primary breast cancer. The potential advantage of CEFci in improving pathologic response still requires further research. The accompanied hematologic and biochemical toxicities, and the catheter-related complications should also be noted.

show abstract

Vinorelbine and Infusional 5-fluorouracil in Anthracycline and Taxane Pre-treated Metastatic Breast Cancer

Cited by 8 publications

References 21 publications

Overcoming Taxane and Anthracycline Resistance

Overcoming Taxane and Anthracycline Resistance

Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study

A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer

Contact Info

Product

Resources

About